Additionally, in NSCLC the presence of G12C is associated with a higher average tumor mutational burden compared to non-G12C mutants or KRAS wild-type tumors, potentially impacting on immunotherapy sensitivity [40]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.